Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
AK112 Injection
Summit Therapeutics
Non-Squamous Non-small Cell Lung Cancer
1 trial -
Acupuncture
Summit Therapeutics
Fatigue
1 trial -
Drug: Ivonescimab Injection
Summit Therapeutics
Metastatic Colorectal Cancer (CRC)
1 trial -
FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab
Summit Therapeutics
Metastatic colorectal cancer
1 trial -
Ivonescimab 10 mg/kg
Summit Therapeutics
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
1 trial -
Ivonescimab Injection
Summit Therapeutics
Non-Small Cell Lung Cancer
2 trials -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion
Summit Therapeutics
Metastatic Non-small Cell Lung Cancer
1 trial -
Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Summit Therapeutics
Metastatic Squamous Non-small Cell Lung Cancer
1 trial -
Ridinilazole
Summit Therapeutics
Clostridioides Difficile Infection
2 trials -
AK112
Summit Therapeutics
Metastatic Colorectal Cancer
1 trial -
Ezutromid
Summit Therapeutics
Duchenne Muscular Dystrophy
1 trial -
Hyperbaric Oxygen Therapy
Summit Therapeutics
TBI Traumatic Brain Injury
1 trial -
Ivonescimab
Summit Therapeutics
Thymus Carcinoma
1 trial -
Ivonescimab
Summit Therapeutics
Ivonescimab
1 trial -
Ivonescimab
Summit Therapeutics
Biliary Tract Cancer
1 trial -
Ivonescimab
Summit Therapeutics
Cutaneous Squamous Cell Carcinoma
1 trial -
Ivonescimab
Summit Therapeutics
Endometrial Cancer
1 trial -
Ivonescimab
Summit Therapeutics
Glioblastoma
1 trial -
Ivonescimab
Summit Therapeutics
Leiomyosarcoma
1 trial -
Ivonescimab
Summit Therapeutics
Lung Cancer (NSCLC)
1 trial -
Ivonescimab
Summit Therapeutics
Metastatic Colorectal Cancer
2 trials -
Ivonescimab
Summit Therapeutics
Metastatic Esophageal Adenocarcinoma
1 trial -
Ivonescimab
Summit Therapeutics
Non-Small Cell Lung Cancer
3 trials -
Ivonescimab
Summit Therapeutics
Pleural Mesotheliomas
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources